These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26237513)

  • 1. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization.
    Gremmel T; Frelinger AL; Michelson AD
    PLoS One; 2015; 10(8):e0134599. PubMed ID: 26237513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40 ligand: a novel target in the fight against cardiovascular disease.
    Vishnevetsky D; Kiyanista VA; Gandhi PJ
    Ann Pharmacother; 2004 Sep; 38(9):1500-8. PubMed ID: 15280513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization.
    Gremmel T; Michelson AD; Frelinger AL
    Platelets; 2016 Jun; 27(4):308-16. PubMed ID: 26556638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy.
    Obradovic S; Djukanovic N; Todorovic Z; Markovic I; Zamaklar-Trifunovic D; Protic D; Ostojic M
    J Atheroscler Thromb; 2015; 22(3):284-92. PubMed ID: 25273829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
    Lim HS; Blann AD; Lip GY
    Circulation; 2004 Jun; 109(21):2524-8. PubMed ID: 15136493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.
    Choudhury A; Chung I; Panja N; Patel J; Lip GYH
    Chest; 2008 Sep; 134(3):574-581. PubMed ID: 18641098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
    Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
    Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease.
    Mason PJ; Chakrabarti S; Albers AA; Rex S; Vitseva O; Varghese S; Freedman JE
    Am J Cardiol; 2005 Nov; 96(10):1365-9. PubMed ID: 16275179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease.
    Azar RR; Kassab R; Zoghbi A; Aboujaoudé S; El-Osta H; Ghorra P; Germanos M; Salamé E
    Am Heart J; 2006 Feb; 151(2):521.e1-521.e4. PubMed ID: 16442924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
    Graff J; Harder S; Wahl O; Scheuermann EH; Gossmann J
    Clin Pharmacol Ther; 2005 Nov; 78(5):468-76. PubMed ID: 16321613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Xiao Z; Théroux P
    J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study.
    Sambu N; Dent H; Englyst N; Warner TD; Leadbeater P; Roderick P; Gray H; Simpson I; Corbett S; Calver A; Morgan J; Curzen N
    Heart; 2011 Oct; 97(20):1661-7. PubMed ID: 21795297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
    Sternberg Z; Chichelli T; Sternberg D; Sawyer R; Ching M; Janicke D; Ambrus JL; Yu J; Munschauer F
    J Stroke Cerebrovasc Dis; 2016 Feb; 25(2):327-34. PubMed ID: 26586373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty.
    Ge H; Zhou Y; Liu X; Nie X; Wang Z; Guo Y; Chen W; Yang Q
    Angiology; 2012 Jan; 63(1):62-6. PubMed ID: 21602258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
    Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
    Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.
    Wykrzykowska JJ; Warnholtz A; de Jaeger P; Curzen N; Oldroyd KG; Collet JP; Ten Berg JM; Rademaker T; Goedhart D; Lissens J; Kint PP; Serruys PW
    J Thromb Thrombolysis; 2009 Nov; 28(4):410-7. PubMed ID: 19504052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.